Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company focused on developing biologic medicines that cross the blood–brain barrier to treat neurodegenerative diseases, lysosomal storage disorders and other serious conditions. The company develops a platform for systemic delivery of enzymes, oligonucleotides and antibodies to the central nervous system, advances translational research published in peer-reviewed journals, maintains biologics manufacturing and clinical supply capabilities, and pursues collaborations with industry, academia and patient communities.
Industries
Nr. of Employees
large (251-1000)
Denali Therapeutics
Patents
Products
AVLAYAH (tividenofusp alfa-eknm)
Registered therapeutic referenced with prescribing information and assigned a permanent J-code (J1757).
AVLAYAH (tividenofusp alfa-eknm)
Registered therapeutic referenced with prescribing information and assigned a permanent J-code (J1757).
Services
Structured collaborations with industry, academic institutions, foundations and enabling technology partners to advance discovery, development and commercialization.
Engagement with patient communities and provision of information about clinical studies and enrollment to support trial conduct and incorporate real-world perspectives.
Structured collaborations with industry, academic institutions, foundations and enabling technology partners to advance discovery, development and commercialization.
Engagement with patient communities and provision of information about clinical studies and enrollment to support trial conduct and incorporate real-world perspectives.
Expertise Areas
- CNS delivery platform development
- Lysosomal storage disorder therapeutics
- Neurodegenerative disease therapeutics
- Biologics process development and scale-up
Key Technologies
- Blood–brain barrier transport platforms
- Transferrin receptor–mediated targeting
- Enzyme replacement therapy for CNS and somatic disease
- Antisense oligonucleotide CNS delivery
News & Updates
Peer-reviewed article reporting an intravenous brain-penetrant enzyme therapy in The New England Journal of Medicine.
Science article describing transferrin receptor–targeted antibody approaches to improve brain delivery and mitigate ARIA.
Science Translational Medicine article on transferrin receptor targeting to enable antisense oligonucleotide transport across the blood–brain barrier.
Peer-reviewed article reporting an intravenous brain-penetrant enzyme therapy in The New England Journal of Medicine.
Science article describing transferrin receptor–targeted antibody approaches to improve brain delivery and mitigate ARIA.
Science Translational Medicine article on transferrin receptor targeting to enable antisense oligonucleotide transport across the blood–brain barrier.